Value2024TTMSelling/general/admin expenses23.1 M20.42 MResearch & development70.47 M78.32 MOperating income-93.53 M-98.74 MNon-Operating Income, Total24.84 M21.89 MInterest expense, net of interest capitalized——Non-Operating Income, excl. Interest Expenses24.88 M21.94 MUnusual income/expense-47 K-52 KPretax income118.37 M124.72 MEquity in earnings——Taxes0—Non-controlling/minority interest——After tax other income/expense——Net income before discontinued operations-68.69 M-122.2 MDiscontinued operations——Net income-68.69 M-122.2 MDilution adjustment140.86 M—Preferred dividends1.74 M—Diluted net income available to common stockholders70.43 M122.2 MBasic earnings per share (Basic EPS)-1.62-2.39Diluted earnings per share (Diluted EPS)-1.62-2.39Average basic shares outstanding43.54 M195.6 MDiluted shares outstanding43.54 M195.6 MEBITDA-92.85 M-97.67 MEBIT-93.53 M-98.74 MCost of revenue50 K0Other cost of goods sold——Depreciation & amortization (cash flow)677 K1.07 M
Fractyl Health Inc
Fractyl Health is a Burlington, Massachusetts-based healthcare company focused on metabolic diseases like obesity and type 2 diabetes. The company developed Revita, an outpatient endoscopic procedure to modify duodenal dysfunction, and Rejuva, a gene therapy platform in preclinical development to enable the pancreas to produce glucagon-like peptide-1.